NCT05046613View on ClinicalTrials.gov

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

Active, not recruitingOBSERVATIONAL
Enrollment

780

Participants

Timeline

Start Date

September 23, 2021

Primary Completion Date

April 30, 2034

Study Completion Date

April 30, 2034

Conditions
Migraine
Interventions
OTHER

Rimegepant

75mg

OTHER

Not taking Rimegepant

No rimegepant

Trial Locations (1)

10001

Pfizer, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

PPD, Part of Thermo Fisher Scientific

INDUSTRY

lead

Pfizer

INDUSTRY